Retinal changes: a mortality risk in non-diabetics

Article

A study published in the September issue of the American Journal of Epidemiology, suggests that retinal changes have possible prognostic implications regarding the survival of persons with diabetes.

A study published in the September issue of the American Journal of Epidemiology, suggests that retinal changes have possible prognostic implications regarding the survival of persons with diabetes.

Despite retinopathy being fairly common among non-diabetics, its prognostic implications are not fully understood. Ronald Klein and colleagues from the University of Wisconsin, USA and the Federal University of Sao Paulo, Brazil hypothesized that retinal alterations are associated with increased mortality. In order to investigate this, they evaluated survival rates among 4,292 non-diabetic participants (age range, 43-84 years) of the Beaver Dam Eye Study.

Retinal photographs were used to classify retinopathy into four groups: no retinopathy, retinal haemorrhage only, retinal micro-aneurysm or moderate or worse retinopathy. Survival was analyzed over a 14-year follow-up period in five-year intervals.

The baseline prevalence of retinopathy was 7.6%. After the 14-year follow-up period it was discovered that moderate retinopathy, at baseline, increased the risk of all-cause mortality by 24% and ischaemic heart disease by more than three-fold.

Based on these results, the researchers believe that retinal changes do have possible prognostic implications regarding the survival of persons without diabetes.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.